Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.038
- Book/Share 2.4743
- PB 22.1197
- Debt/Equity 0.1154
- CurrentRatio 1.5942
- ROIC 0.2452
- MktCap 11791797420.0
- FreeCF/Share 1.0821
- PFCF 49.0881
- PE 73.9042
- Debt/Assets 0.0711
- DivYield 0
- ROE 0.3597
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Hims & Hers: Growth, Strategic Partnerships, And Operational Leverage (Upgrade)
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health's rapid revenue and subscriber growth, plus improving cash generation, highlight strong business momentum and brand strength. Gross margins have declined due to lower-margin obesity products, but SG&A as a percentage of revenue is improving, supporting better operating leverage. The recent Novo Nordisk collaboration and capital raise position Hims for expansion, though reliance on GLP-1 drugs and competition are key risks.
Read More
Hims & Hers Health, Inc. (HIMS) is a Great Momentum Stock: Should You Buy?
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Top Health & Fitness Stocks to Buy for the Wellness Boom
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.
Read More
Cautious? Risky? Our Volatility Scorecard Can Help
Published: May 13, 2025 by: Schaeffers Research
Sentiment: Neutral
Subscribers to Chart of the Week received this commentary on Sunday, May 11.
Read More
Hims & Hers Health Stock: A Rare High-Growth Value Play In Plain Sight
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Rarely I see high-growth, value plays in the market. I think Hims & Hers Health is such a rare case: a world-class, high-growth company still being valued as a risky startup. A DCF model based on 2030 guidance suggests a $64 fair value per share, with potential to far exceed that price due to management's conservative guidance. I think HIMS stock's fair value is above $84 per share, with potential to upwards of $300 per share in a bullish case scenario (2030 DCF model).
Read More
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.
Read More
Hims & Hers: Still Undervalued For These 2 Reasons
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Hims' operating leverage was outstanding at 5:1 over revenue growth. This is irrefutable proof of a scalable business. Hims' new TAMs should provide billions to the top line, hundreds of millions to the bottom, and dollars to EPS. Hims is likely a decade-plus ahead of competitors at this point with 'The Hims Trinity.'
Read More
Hims & Hers: Short-Lived Turbulence To Be Followed By New Phase Of Profitable Growth
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth, driven by strong uptake of personalized GLP-1 offerings. Despite a projected Q2 revenue decline due to product transitions, management reaffirmed full-year 2025 revenue guidance of $2.3–2.4B and raised adj. EBITDA guidance to $295–335M. Long-term growth prospects remain strong, with a target of $6.5B+ revenue and $1.3B+ adj. EBITDA by 2030, driven by TAM penetration, new specialties, and AI integration.
Read More
Hims & Hers: Wegovy Deal Opens New Growth Chapter - Missed The Rally? Selling Puts Could Yield 30%
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health rebounded from a 60% stock drop by partnering with Novo Nordisk, offering Wegovy at a competitive price, boosting accessibility and growth. Q1 earnings were exceptional with 111% YoY revenue growth and a 345% increase in net income, highlighting a sustainable and resilient business model. The company's personalized healthcare approach and new product launches, like low testosterone and menopause support, are driving subscriber growth and higher revenue per subscriber.
Read More
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Read More
Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced of.
Read More
Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started
Published: May 08, 2025 by: Benzinga
Sentiment: Positive
If short sellers were hoping for a flop from Hims & Hers Health Inc. HIMS, they may want to check their risk management settings. The telehealth disruptor dropped first-quarter earnings after the bell on Monday, and instead of the crash shorts were counting on, the market got a bullish cocktail: strong guidance, solid revenue growth and a headline-making partnership with Novo Nordisk A/S NVO.
Read More
Hims & Hers: The Road To Blue Chip Status
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
Personalized subscribers grew 136% YoY, reflecting a fundamental shift towards precision medicine. Despite declining gross margins, HIMS achieved 13pp of operating leverage in Q1. This is by far HIMS' best quarter to date. The markets need to put some respect on Andrew Dudum and his world-class team.
Read More
Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply pe.
Read More
Hims & Hers: 2030 Guidance Indicates Big Upside
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive
Management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, focusing on personalized healthcare and geographic expansion. Anticipating management's guidance for 2025 and 2030, Hims & Hers could be undervalued by up to 62%. Apart from the guidance, the company needs to achieve growth rates in the mid-teens% to justify the current valuation.
Read More
Surging Earnings Estimates Signal Upside for Hims & Hers Health (HIMS) Stock
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Hims & Hers: Short Squeeze Or Strong Fundamentals? (Rating Downgrade)
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. Q1 results beat the Street's expectations, as I anticipated in February. The company reaffirmed FY 2025 guidance and increased the EBITDA range for the year. That said, I believe the rally on May 6 was driven by the high short interest and not by fundamentals. The availability of Eli Lilly and Novo Nordisk weight loss drugs on the Hims platform is significant, but the easing of drug shortages could affect Q2 subscriber numbers.
Read More
Hims & Hers Shows It's More Than Just GLP-1 Drugs
Published: May 07, 2025 by: 24/7 Wall Street
Sentiment: Positive
Hims & Hers Health (HIMS) released first-quarter earnings after the closing bell on Monday and saw shares surge on the robust numbers.
Read More
Hims & Hers Health: Healthcare Disruptor Building A Durable Moat (Initiate With Buy)
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health reported strong Q1 '25 earnings, with 111% YoY sales growth and 38% subscriber growth. The company boasts over a 70% gross margin, 90% recurring revenue, and a compelling flywheel effect driven by machine learning and big data analytics. Risks include the untested business model, potential legal issues, and the complexity of international expansion, but the growth potential presented far outweighs these concerns.
Read More
Options Bulls Blast Surging Telehealth Stock After Earnings
Published: May 06, 2025 by: Schaeffers Research
Sentiment: Positive
Hims & Hers Health Inc (NYSE:HIMS) beat top- and bottom-line estimates for the first quarter, with net profits seeing a 300% jump.
Read More
2 Reasons Hims & Hers Will Break $50s - Buy Post Earnings
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. impressed with strong Q1 earnings, subscriber growth, and a promising partnership with Novo Nordisk, but didn't guide as well as we all hoped. The two reasons I'm buying are 1. The partnership with Novo should expand to include Ozempic and 2. Oral pill approval from the FDA should be achieved and boost financials. I think we're still at the start of Hims' comeback story, and the stock is still cheap considering its upside potential.
Read More
Hims & Hers stock jumps after blowout quarter, long-term guidance stuns Street
Published: May 06, 2025 by: Proactive Investors
Sentiment: Positive
Shares of Hims & Hers Health (HIMS) surged 10% on Tuesday morning after the telehealth company posted first-quarter results that far surpassed Wall Street expectations and unveiled an ambitious roadmap targeting $6.5 billion in revenue by 2030. Revenue in the quarter more than doubled to $586 million, up 111% from a year earlier and well ahead of analysts' average estimate of $538.9 million.
Read More
Hims & Hers Stock Rises on Fundamentals and Squeeze Potential
Published: May 06, 2025 by: MarketBeat
Sentiment: Positive
There are only a few companies that come around every half-decade or so that really get the gears turning in terms of having the right fundamental makeup for value investors. It just so happens that these companies (when caught early on) are too small to even be on the radar of the bigger sharks in the financial markets, which is where average retail investors get the chance to act on an inherent advantage.
Read More
HIMS Earnings Rally, Guidance Powers CEG, DASH Moves Lower
Published: May 06, 2025 by: Schwab Network
Sentiment: Positive
Hims & Hers (HIMS) rallied this morning after earnings, reversing initial selling action following the report. Diane King Hall believes a huge jump in revenue and its Wegovy deal are behind the positive sentiment.
Read More
Hims & Hers: Strong Q1 Masks Problematic Long-Term Value Proposition
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health, Inc.'s Q1 2025 earnings show impressive growth, with revenues up 111% year-on-year and net income rising significantly, but HIMS shares dropped 8% pre-market. The company's success has been heavily tied to access to weight loss drugs like semaglutide; however, the end of the drug shortage period poses challenges. Hims' new partnership with Novo Nordisk aims to sustain growth, but competition from direct-to-consumer platforms raises concerns about long-term differentiation.
Read More
HIMS Growth Potential, Weight-loss Drug Pipeline
Published: May 06, 2025 by: Schwab Network
Sentiment: Positive
Raul Shah says Hims & Hers (HIMS) latest earnings report was a win for two reasons: A lot of operating leverage and expanding growth. Raul believes HIMS guidance was "implausible" in his estimation, adding the company will grow faster than even the company anticipates.
Read More
HIMS Earnings Ahead: Wegovy Offers Upside, Analysts Advise Caution
Published: May 05, 2025 by: Schwab Network
Sentiment: Neutral
"There's a sense of caution" heading into Hims & Hers (HIMS) earnings, says Caroline Woods. The telehealth company is up over 65% so far in 2025 but has fallen more than 40% off its February highs.
Read More
Hims & Hers brings former Amazon executive into C-suite
Published: May 05, 2025 by: CNBC
Sentiment: Positive
Hims & Hers Health announced Nader Kabbani will join the telehealth company as its new chief operations officer. Kabbani spent nearly 20 years at Amazon, where he oversaw the launch of Amazon Pharmacy, the company's acquisition of PillPack and its global Covid-19 Vaccination Task Force.
Read More
Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer
Published: May 05, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. Kabbani brings more than two decades of experience building global operational infrastructure at.
Read More
Can Sustained Product Demand Drive HIMS Stock Before Q1 Earnings?
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the first quarter of 2025.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Mr. Andrew Dudum
- Employees 1637